Document is current
Any future updates will be listed below
-
Authors
Labiano, Ibone
Huerta, Ana E.
Alsina, Maria http://orcid.org/0000-0003-4835-7159
Arasanz, Hugo
Castro, Natalia
Mendaza, Saioa
Lecumberri, Arturo
Gonzalez-Borja, Iranzu
Guerrero-Setas, David
Patiño-Garcia, Ana
Alkorta-Aranburu, Gorka
Hernández-Garcia, Irene
Arrazubi, Virginia
Mata, Elena
Gomez, David
Viudez, Antonio
Vera, Ruth
-
Funding
Funding for this research was provided by:
Spanish National Agency of Research (FJC2021-046521-I)
Government of Navarra in the La Caixa Program
Clínico Junior 2019 scholarship from the Spanish Association Against Cancer (CLJUN19010ARAS)
Clinico Junior 2023 scholarship from the Spanish Association Against Cancer (CLJUN234885LECU)
Department of Economic Development of Navarre (0011-1408-2017-000026)
- License Information
-
More Information
Article History
Received: 19 April 2024
Accepted: 9 July 2024
First Online: 13 July 2024
Competing interests
: IL, AEH, SM, IGB, DGS, EM, DG and AV declare no conflict of interest; MA has been involved as a consultant for advisory roles with Amgen, BMS, MSD, Lilly and Servier; HA has been involved as a consultant for advisory roles from Astra Zeneca and for trial coordination from Ferrer Farma; NC: has received speaker honoraria from Roche and Pierre Fabre; AL has received speaker honoraria from Pierre-Fabre; APG has received speaker honoraria from Merck Sharp; GAA has received speaker honoraria from ThermoFisher and Roche; IHG has received speaker honoraria from Astra Zeneca; VA has been involved as a consultant for advisory roles and received speaker honoraria from MSD, Bristol, Lilly, Astra-Zeneca and Pierre-Fabre. RV has been involved as a consultant for advisory roles with Servier, Roche and Merck Sharp and has received speaker honoraria from Roche, Amgen, Merck Sharp and Dohme, Astra Zeneca.
